[kidney] disease," study lead author Dr. Rochelle Walensky said in the news release. She's chief of infectious diseases at the Massachusetts General Hospital and a professor at the Harvard Medical School in Boston.
"Clinicians are subjected to often intense promotional activity generated both by academic and commercial interests when new medications and data are generated," explained Dr. Joseph McGowan, medical director of the Northwell Health HIV Service Line Program, in Manhasset, N.Y. McGowan said the new analysis has some shortcomings -- for example, the authors put the projected cost of a generic PrEP at 50% less than brand-name options, although at this point in time the actual price for patients in September is uncertain.But McGowan, who had no role in the new study, said that the researchers make some important points.
He believes that Descovy might still be the better, more cost-effective option for some patients over the age of 55, because their risks for bone and kidney complications is higher.
Stop nasty activities that cause HIV. Problem solved.
Money over people...where have we heard that before. Oh yeah, everyday with the moronic White House, and Johnson & Johnson pushing opioids on the unsuspecting masses!
PrEP